Association of rs622342 SLC22A1 with the short-term changes of lipid and carbohydrate metabolism indicators in different variants of early carbohydrate metabolism disorders management in women

Objective : to analyze the association of rs622342 SLC22A1 with the short-term changes in fat and carbohydrate metabolism parameters in various types of early carbohydrate metabolism disorders therapy. Materials and methods : the results of management of 89 patients with excess body weight and risk factors for type 2 diabetes mellitus development were analyzed. For 3 months, 53 patients followed diet therapy, 36 patients took metformin in addition to the diet. All of the patients were genotyped for rs622342 SLC22A1. Also initially and 3 months after the beginning of therapy fasting plasma glucose, glycosylated hemoglobin, total cholesterol, low-density and high-density lipoproteins, tryglicerides were measured. Statistical processing was carried out using parametric and non-parametric criteria. Results : 3 months after the start of diet therapy, homozygous СС-carriers of the rs622342 SLC22A1 showed a significant decrease in total cholesterol and triglycerides compared with A-allele carriers. These changes were not observed when metformin was added to diet therapy. There were no significant differences in changes of fasting plasma glucose and glycated hemoglobin levels in groups with different management. Conclusions : carriers of CC rs622342 SLC22A1 are characterized with the significant decrease in total cholesterol and triglycerides levels compared to the A-allele carriers after 3 months of standard diet therapy; when metformin is added to the treatment regimen, these changes are not observed.